Tempus AI: The Surprising Star of 2022 with an 82% YTD Return
Have you been keeping an eye on the stock market lately? If so, you might have noticed a small but mighty player making waves in the tech world: Tempus AI (TEM). This Chicago-based healthcare technology company has been delivering some impressive returns, with a whopping 82% YTD (Year to Date) as of now.
Outperforming the Market and AI-themed Stocks
Now, you might be thinking, “82% return? That’s impressive, but what does it really mean?” Well, let me put it into perspective for you. The S&P 500, a widely followed stock market index, has only managed a 26% return in the same timeframe. And when it comes to AI-themed stocks, Tempus AI is outshining them all. For instance, NVIDIA, a tech giant known for its graphics processing units (GPUs) and AI capabilities, has only seen a 45% return this year.
The Acquisition of Ambry Genetics: A Game Changer
So, what’s Tempus AI’s secret? Well, they’ve been making some strategic moves. A couple of days back, they announced the acquisition of Ambry Genetics, a leading genetic testing laboratory. This move is largely positive for Tempus AI, as it will give them access to a vast amount of genetic data, which will help them improve their AI algorithms and expand their offerings in the healthcare industry.
Preliminary Earnings: No Major Surprises
Now, you might be thinking, “But what about their earnings? Aren’t they a factor in their stock performance?” Yes, earnings are important, but let me break it down for you. Tempus AI released their preliminary Q4 and FY earnings last month, and while they were solid, they didn’t have any major surprises. Revenue came in at $121.2 million for Q4, which was a 52% increase year over year. For the full year, they reported revenue of $333.4 million, a 58% increase from the previous year.
Impact on You: Personalized Medicine
Now, let’s talk about what this means for you. Tempus AI is using AI and machine learning to help doctors make more accurate diagnoses and personalize treatment plans for their patients. With the acquisition of Ambry Genetics, they’ll be able to analyze even more genetic data, leading to better and more personalized care. So, if you’re a patient, this could mean better outcomes for you.
Impact on the World: A Healthier Future
On a larger scale, Tempus AI’s advancements in AI and personalized medicine could lead to a healthier future for all of us. By analyzing vast amounts of data, they can help doctors make more accurate diagnoses and develop more effective treatments. This could lead to better health outcomes, lower healthcare costs, and a happier, healthier population.
Conclusion
So there you have it, folks. Tempus AI’s impressive YTD return, strategic acquisitions, and solid earnings are making waves in the tech and healthcare industries. And with their focus on personalized medicine, they’re not just making money – they’re making a difference. So, keep an eye on Tempus AI, and who knows? You might just be a part of the future of healthcare.
- Tempus AI is delivering impressive returns, with an 82% YTD as of now
- They’ve outperformed the broader market and AI-themed stocks
- They recently acquired Ambry Genetics, giving them access to a vast amount of genetic data
- Their preliminary earnings were solid, but didn’t have any major surprises
- Tempus AI’s focus on personalized medicine could lead to better health outcomes and lower healthcare costs
